Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis

Published:2018-07-04 Issue:3 Volume:171 Page:535-544
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Wang Jiayu,Xu Binghe^ORCID,Wang Wenna,Zhai Xiaoyu,Chen Xuelian

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-018-4867-y/fulltext.html

Reference37 articles.

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. https://doi.org/10.3322/caac.20107

2. Li T, Mello-Thoms C, Brennan PC (2016) Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res Treat 159:395–406. https://doi.org/10.1007/s10549-016-3947-0

3. Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132. https://doi.org/10.3322/caac.21338

4. Kümler I, Knoop AS, Jessing CAR et al (2016) Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. ESMO Open 1:e000062. https://doi.org/10.1136/esmoopen-2016-000062

5. Rugo HS, Rumble RB, Macrae E et al (2016) Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 34:3069–3103. https://doi.org/10.1200/JCO.2016.67.1487

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DREAM On, DREAM Off: A Review of the Estrogen Paradox in Luminal A Breast Cancers;Biomedicines;2024-06-12

2. Combined oral low-dose cyclophosphamide endocrine therapy may improve clinical response among patients with metastatic breast cancer via Tregs in TLSs;Scientific Reports;2024-06-11

3. Oral low-dose cyclophosphamide with endocrine therapy through effects on Tregs in TLSs may improve clinical response in elderly metastatic breast cancer patients;2023-12-04

4. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis;BMC Cancer;2023-08-31

5. Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting;BMC Proceedings;2021-08